Stay updated on Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference4%
- Check8 days agoChange DetectedThe page has removed specific future updates regarding the modernization of ClinicalTrials.gov data ingest and the associated API user input, along with the previous version details.SummaryDifference5%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check30 days agoNo Change Detected
- Check37 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.3%
- Check44 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check73 days agoChange DetectedThe web page has updated its version from v2.15.0 to v2.15.2 and has changed the date from April 6, 2025, to April 30, 2025.SummaryDifference0.6%
Stay in the know with updates to Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Vibostolimab vs Pembrolizumab in Melanoma Clinical Trial page.